Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

 
• By Lucie Ellis-Taitt
  
Two wild goats play-fight on the edge of a rock cliff with horns interlocked.
Lilly's abemaciclib will face off with Pfizer's Ibrance if approved in 2018
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D